Head-to-head evidence
Gabapentin vs Pregabalin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: α2δ subunit of voltage-gated calcium channels · full Epilepsy pipeline
Gabapentin
Marketed by Pfizer and partners
NCT00007670 · Phase 3 · completed
The study used randomization, double blinding, and an active carbamazepine control in a relatively large sample of 720 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Pregabalin
Marketed by Pfizer and partners
NCT01463306 · Phase 3 · completed
This was an open-label study with no randomization and no concurrent placebo or active-control arm, although it included 605 participants and some had continued from earlier studies. The primary outcomes were reported descriptively without a formal current-study comparison or statistical test, so the findings cannot establish comparative efficacy or safety.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gabapentin's landscape · Pregabalin's landscape